Tenderwize
Retour à la recherche

Open-house rebate agreements for infliximab

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Jan 31, 2028 · 468 days left·Open·Supplies
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Infliximab, ATC L04AB02

18/100

Score d'opportunité

Needs reviewHigh complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

18 / 100

Complexité

68 / 100

Facteurs de risque

The structured notice suggests a long-running open-house arrangement, but the extracted XML notice says the procedure w...

The structured data marks electronic submission as not allowed, while the notice text allows electronic submission with...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Jan 31, 2028

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Non-exclusive open-house rebate agreements for medicinal products with the active substance infliximab (ATC L04AB02).
  • Exclusion of medicines listed on the BfArM list under § 35 Abs. 5a SGB V (children's medicines).
Afficher le résumé complet

This is an open-house pharmaceutical supply arrangement for infliximab (CPV 33600000) by AOK Rheinland-Pfalz/Saarland. The structured notice indicates a 24-month term starting 2026-04-01, but the extracted TED XML notice states the open-house procedure was lifted effective 2026-05-31 and no new contracts can be concluded. This creates a material inconsistency that materially affects bid viability. The procedure is non-exclusive, with no selection decision and no negotiated terms, but participation is limited to pharmaceutical companies and requires specific submission formats and proof of marketability/authorization.

Risques

The structured notice suggests a long-running open-house arrangement, but the extracted XML notice says the procedure w...

The structured data marks electronic submission as not allowed, while the notice text allows electronic submission with...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Only approved and marketable medicines in Germany may be supplied under the contract.

Eligibility

  • Only pharmaceutical companies are eligible to participate.

Administrative

  • If the product is not yet listed in Lauer-Taxe at submission time, an AMIce public-section extract must be provided.

Acheteur

Localisation

Eisenberg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE271900642

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreements for infliximab

Single lot covering non-exclusive open-house rebate agreements for medicinal products containing infliximab (ATC L04AB02). The scope excludes medicines on the BfArM list under § 35 Abs. 5a SGB V (children's medicines). Contract terms are uniform for all participants; no individual negotiations are conducted. The extracted XML notice says the procedure was withdrawn effective 2026-05-31, so new contract entry is no longer possible according to that source.

SuppliesEU fundedElectronic submission

Localisation

Eisenberg, Germany

Durée

Mar 2026 - Mar 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Jan 31, 2028

Détails de la procédure

Date de publication
08 Apr 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
241570-2026

Documents (1)

Appels d'offres similaires